Unsurpassed in inhibitor safety - clinically proven1

 

New generation VWF/Factor VIII concentrate

 

Highly purified native Factor IX

 

Highly purified native Factor IX

1  Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate(®) : interim report from an ongoing prospective clinical study. Klukowska, Komrska, Jansen, Laguna - Haemophilia 2010 Dec 1. doi: 10.1111/j.1365-2516.2010.02428.x [Epub ahead of print]

Patients : Coagulation disorders

Octapharma develops and manufactures high-purity coagulation factor concentrates for patients with bleeding disorders.

 

These products meet the highest standards in terms of safety and efficacy, thereby significantly improving the quality of life for people with disorders like haemophilia.

 

We are also developing the first commercial recombinant coagulation Factor VIII, which is designed to reduce the overall immunogenic challenge (and resulting inhibitor formation) in patients with haemophilia A.

Bleeding disorders

"Bleeding disorder" is a general term for a wide range of medical problems that lead to poor blood clotting and continuous bleeding, including:

  • Haemophilia A
  • Haemophilia B
  • von Willebrand disease (VWD)

In people with such disorders, clotting factors like Factor VIII, Factor IX or von Willebrand factor (VWF) are missing or don't work as they should. This causes these people to bleed for a longer time than those whose blood factor levels are normal. Early on-demand or prophylactic therapy that replaces the missing coagulation factor is able to effectively control or prevent acute bleeding in this group of patients.